Felicitas S. Boretti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felicitas S. Boretti has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Regina Hofmann-Lehmann
Clinical Laboratory, Department of Clinical Diagnostics and Services and Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Switzerland
23 shared publications - Nadja S. Sieber-Ruckstuhl
Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
14 shared publications - Barbara Riond
Clinical Laboratory, Department for Clinical Services and Diagnostics, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland
11 shared publications - Marina Luisa Meli
Clinical Laboratory, Department of Clinical Diagnostics and Services and Center for Clinical Studies, Vetsuisse Faculty, University of Zurich, Switzerland
9 shared publications - Marilisa Novacco
Department of Veterinary Sciences and Public Health, University of Milan, Milan, Italy
7 shared publications - Barbara Willi
Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in BMC Veterinary Research
Adrenal steroid profiles measured by liquid chromatography-mass spectrometry in dogs with primary hypoadrenocorticism and healthy controls
Background: Primary hypoadrenocorticism (pHA) in dogs typically results from immune-mediated destruction of the adrenal cortex, causing glucocorticoid and mineralocorticoid deficiencies. Whether broader alterations in adrenal steroidogenesis, particularly within the androgen axis, also occur has not been systematically investigated. The aim of this study was to describe adrenal steroid profiles in dogs with pHA using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and to compare them with those of healthy control dogs, stratified by sex and reproductive status. Serum samples from 43 dogs with hyponatremic, hyperkalemic pHA (either newly diagnosed and untreated, or receiving prednisolone and desoxycorticosterone pivalate [DOCP]) and 35 healthy control dogs were analyzed. Fourteen steroids, including common precursors, mineralocorticoids, glucocorticoids, and androgens, were quantified by LC-MS/MS. Gonadectomized dogs formed the primary study population; intact dogs were evaluated separately. Results: Cortisol, 11-deoxycortisol, corticosterone, and cortisone concentrations were significantly lower in dogs with pHA than in healthy controls, consistent with primary adrenocortical failure. Beyond these expected findings, several unanticipated alterations were identified. Progesterone and 21-deoxycortisol concentrations were higher, and 17α-hydroxyprogesterone and androstenedione concentrations were lower in dogs with pHA than in healthy controls. Dihydrotestosterone concentrations showed a divergent pattern, being lower in newly diagnosed dogs and higher in treated dogs compared with healthy controls. 11-deoxycorticosterone concentrations were markedly increased in DOCP-treated dogs and correlated positively with DOCP dosage, consistent with a treatment-related effect. Dehydroepiandrosterone and dehydroepiandrosterone sulfate were below the limit of quantification in most dogs, precluding firm conclusions. Several steroids differed according to sex or gonadal status, underlining the importance of these factors in the interpretation of canine steroid profiles. Conclusions: Dogs with pHA show not only reduced glucocorticoid- and mineralocorticoid-related steroids, but also distinct alterations in steroid intermediates and androgens. The alterations within the androgen axis are complex and do not support a simple uniform androgen deficiency pattern. These findings support the concept of a global disruption of adrenal steroidogenesis in canine pHA and suggest a possible application of LC-MS/MS-based multisteroid profiling for characterizing physiological and pathophysiological aspects of adrenal steroidogenesis in this disease.
- 15 October 2026
- Published by Springer Nature in BMC Veterinary Research
Open AccessAdrenal steroid profiles measured by liquid chromatography-mass spectrometry in dogs with primary hypoadrenocorticism and healthy controls
Background: Primary hypoadrenocorticism (pHA) in dogs typically results from immune-mediated destruction of the adrenal cortex, causing glucocorticoid and mineralocorticoid deficiencies. Whether broader alterations in adrenal steroidogenesis, particularly within the androgen axis, also occur has not been systematically investigated. The aim of this study was to describe adrenal steroid profiles in dogs with pHA using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and to compare them with those of healthy control dogs, stratified by sex and reproductive status. Serum samples from 43 dogs with hyponatremic, hyperkalemic pHA (either newly diagnosed and untreated, or receiving prednisolone and desoxycorticosterone pivalate [DOCP]) and 35 healthy control dogs were analyzed. Fourteen steroids, including common precursors, mineralocorticoids, glucocorticoids, and androgens, were quantified by LC-MS/MS. Gonadectomized dogs formed the primary study population; intact dogs were evaluated separately. Results: Cortisol, 11-deoxycortisol, corticosterone, and cortisone concentrations were significantly lower in dogs with pHA than in healthy controls, consistent with primary adrenocortical failure. Beyond these expected findings, several unanticipated alterations were identified. Progesterone and 21-deoxycortisol concentrations were higher, and 17α-hydroxyprogesterone and androstenedione concentrations were lower in dogs with pHA than in healthy controls. Dihydrotestosterone concentrations showed a divergent pattern, being lower in newly diagnosed dogs and higher in treated dogs compared with healthy controls. 11-deoxycorticosterone concentrations were markedly increased in DOCP-treated dogs and correlated positively with DOCP dosage, consistent with a treatment-related effect. Dehydroepiandrosterone and dehydroepiandrosterone sulfate were below the limit of quantification in most dogs, precluding firm conclusions. Several steroids differed according to sex or gonadal status, underlining the importance of these factors in the interpretation of canine steroid profiles. Conclusions: Dogs with pHA show not only reduced glucocorticoid- and mineralocorticoid-related steroids, but also distinct alterations in steroid intermediates and androgens. The alterations within the androgen axis are complex and do not support a simple uniform androgen deficiency pattern. These findings support the concept of a global disruption of adrenal steroidogenesis in canine pHA and suggest a possible application of LC-MS/MS-based multisteroid profiling for characterizing physiological and pathophysiological aspects of adrenal steroidogenesis in this disease.
- Open Access
- 8 August 2026
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1)
Evaluating plasma renin activity as a monitoring parameter for mineralocorticoid treatment in dogs with primary hypoadrenocorticism
Background: In human medicine, plasma renin activity (PRA) is used to assess mineralocorticoid treatment adequacy in hypoadrenocorticism, with elevated levels indicating under-replacement and suppressed levels over-replacement. In dogs with primary hypoadrenocorticism, PRA is increased before treatment and decreases with treatment, but its value as a monitoring parameter remains uncertain. The objective of this study was to evaluate PRA as a marker to guide mineralocorticoid dosing in dogs with primary hypoadrenocorticism. A total of 52 PRA measurements were collected from 28 dogs during scheduled desoxycorticosterone pivalate (DOCP) treatment visits. All dogs had received DOCP and prednisolone for at least five months. PRA was measured by ELISA detecting angiotensin I. Results: Median PRA was 1.6 ng/mL/h (range, 0–19.2), with 19 values above, 17 within, and 16 below the reference interval. PRA showed moderate correlations with potassium ( p = 0.009, 𝛒 = 0.36), sodium ( p = 0.02, 𝛒 = -0.33), the sodium-to-potassium (Na/K) ratio ( p = 0.006, 𝛒 = -0.38), and DOCP dose ( p = 0.02, 𝛒 = -0.34), while urine specific gravity correlated with DOCP dose ( p = 0.01, 𝛒 = -0.50). Compared with visits with decreased PRA, visits with increased PRA had a significantly lower Na/K ratio ( p = 0.048). Increased PRA occurred more frequently during visits with concurrent disease ( p = 0.005); concurrent disease was also associated with higher creatinine concentrations ( p = 0.023) and lower DOCP doses ( p = 0.004). In subgroup analyses, chronic enteropathy was associated with higher potassium concentrations ( p = 0.003), lower Na/K ratios ( p = 0.009), and higher DOCP doses ( p < 0.001), whereas chronic kidney disease was associated with higher creatinine concentrations ( p < 0.001) and lower DOCP doses ( p < 0.001). Clinical assessment and PRA status were concordant in 48% of visits. Conclusions: PRA may provide additional information for monitoring mineralocorticoid treatment in dogs with hypoadrenocorticism treated with DOCP. However, its interpretation can be challenging, as it often does not match electrolyte results and both PRA and electrolytes may be affected by other diseases. Therefore, PRA should be interpreted as a supportive parameter within the clinical context.
- 8 August 2026
- Published by Springer Nature in BMC Veterinary Research
- Vol. 22 (1)
Open AccessEvaluating plasma renin activity as a monitoring parameter for mineralocorticoid treatment in dogs with primary hypoadrenocorticism
Background: In human medicine, plasma renin activity (PRA) is used to assess mineralocorticoid treatment adequacy in hypoadrenocorticism, with elevated levels indicating under-replacement and suppressed levels over-replacement. In dogs with primary hypoadrenocorticism, PRA is increased before treatment and decreases with treatment, but its value as a monitoring parameter remains uncertain. The objective of this study was to evaluate PRA as a marker to guide mineralocorticoid dosing in dogs with primary hypoadrenocorticism. A total of 52 PRA measurements were collected from 28 dogs during scheduled desoxycorticosterone pivalate (DOCP) treatment visits. All dogs had received DOCP and prednisolone for at least five months. PRA was measured by ELISA detecting angiotensin I. Results: Median PRA was 1.6 ng/mL/h (range, 0–19.2), with 19 values above, 17 within, and 16 below the reference interval. PRA showed moderate correlations with potassium ( p = 0.009, 𝛒 = 0.36), sodium ( p = 0.02, 𝛒 = -0.33), the sodium-to-potassium (Na/K) ratio ( p = 0.006, 𝛒 = -0.38), and DOCP dose ( p = 0.02, 𝛒 = -0.34), while urine specific gravity correlated with DOCP dose ( p = 0.01, 𝛒 = -0.50). Compared with visits with decreased PRA, visits with increased PRA had a significantly lower Na/K ratio ( p = 0.048). Increased PRA occurred more frequently during visits with concurrent disease ( p = 0.005); concurrent disease was also associated with higher creatinine concentrations ( p = 0.023) and lower DOCP doses ( p = 0.004). In subgroup analyses, chronic enteropathy was associated with higher potassium concentrations ( p = 0.003), lower Na/K ratios ( p = 0.009), and higher DOCP doses ( p < 0.001), whereas chronic kidney disease was associated with higher creatinine concentrations ( p < 0.001) and lower DOCP doses ( p < 0.001). Clinical assessment and PRA status were concordant in 48% of visits. Conclusions: PRA may provide additional information for monitoring mineralocorticoid treatment in dogs with hypoadrenocorticism treated with DOCP. However, its interpretation can be challenging, as it often does not match electrolyte results and both PRA and electrolytes may be affected by other diseases. Therefore, PRA should be interpreted as a supportive parameter within the clinical context.
- Open Access
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1)
Longitudinal assessment of thyroid function in dogs with hypoadrenocorticism: Clinical outcomes and prevalence of autoantibodies
Background: Knowledge about primary hypoadrenocorticism coexisting with immune-mediated thyroiditis (Schmidt's syndrome) in dogs is limited. Objective: To evaluate thyroid function in dogs with naturally occurring hypoadrenocorticism before and during treatment. Animals: Sixty-six client-owned dogs. Methods: Measurement of canine thyroid stimulating hormone (cTSH), total thyroxine (T4), free thyroxine, and autoantibodies against thyroglobulin, T4, and total triiodothyronine. Results: Thirty-eight dogs were assessed before and 28 during treatment. Follow-up data were available for 24/38 and 17/28 dogs, with median follow-up duration of 3.8 years (range, <1.0-8.8 years) and 4 years (range, 1.1 weeks to 10.5 years), respectively. Canine thyroid stimulating hormone was above the reference range at the time of diagnosis of hypoadrenocorticism in 10 of 38 dogs but decreased into the reference range in 7 for which follow-up data was available. Hypothyroidism was confirmed in 5 dogs at a median age of 11 years (range, 7-15 years). In 4 dogs, the condition was diagnosed after a median treatment duration of 5.75 years (range, 2.6-10 years), while in 1 dog, the diagnosis was made concurrently. One dog had detectable thyroid autoantibodies. Conclusions and Clinical Relevance: Hypothyroidism occurs as a rare concurrent condition in dogs with hypoadrenocorticism, potentially at any phase of treatment. Close monitoring of cTSH levels in these dogs could be beneficial, as early changes might indicate the onset of hypothyroidism. The low prevalence of detectable thyroid autoantibodies suggests that nonimmune mechanisms might contribute to thyroid dysfunction.
- 1 January 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (1)
Open AccessLongitudinal assessment of thyroid function in dogs with hypoadrenocorticism: Clinical outcomes and prevalence of autoantibodies
Background: Knowledge about primary hypoadrenocorticism coexisting with immune-mediated thyroiditis (Schmidt's syndrome) in dogs is limited. Objective: To evaluate thyroid function in dogs with naturally occurring hypoadrenocorticism before and during treatment. Animals: Sixty-six client-owned dogs. Methods: Measurement of canine thyroid stimulating hormone (cTSH), total thyroxine (T4), free thyroxine, and autoantibodies against thyroglobulin, T4, and total triiodothyronine. Results: Thirty-eight dogs were assessed before and 28 during treatment. Follow-up data were available for 24/38 and 17/28 dogs, with median follow-up duration of 3.8 years (range, <1.0-8.8 years) and 4 years (range, 1.1 weeks to 10.5 years), respectively. Canine thyroid stimulating hormone was above the reference range at the time of diagnosis of hypoadrenocorticism in 10 of 38 dogs but decreased into the reference range in 7 for which follow-up data was available. Hypothyroidism was confirmed in 5 dogs at a median age of 11 years (range, 7-15 years). In 4 dogs, the condition was diagnosed after a median treatment duration of 5.75 years (range, 2.6-10 years), while in 1 dog, the diagnosis was made concurrently. One dog had detectable thyroid autoantibodies. Conclusions and Clinical Relevance: Hypothyroidism occurs as a rare concurrent condition in dogs with hypoadrenocorticism, potentially at any phase of treatment. Close monitoring of cTSH levels in these dogs could be beneficial, as early changes might indicate the onset of hypothyroidism. The low prevalence of detectable thyroid autoantibodies suggests that nonimmune mechanisms might contribute to thyroid dysfunction.
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (2) , 420-427
Clinical features and long-term management of cats with primary hypoadrenocorticism using desoxycorticosterone pivalate and prednisolone
Background: Primary hypoadrenocorticism (PH) is rare in cats and knowledge about treatment is sparse. Objective: To describe cats with PH with a focus on long-term treatment. Animals: Eleven cats with naturally occurring PH. Methods: Descriptive case series with data on signalment, clinicopathological findings, adrenal width, and doses of desoxycorticosterone pivalate (DOCP) and prednisolone during a follow-up period of >12 months. Results: Cats ranged from 2 to 10 years (median 6.5); 6 cats were British Shorthair. Most common signs were reduced general condition and lethargy, anorexia, dehydration, obstipation, weakness, weight loss, and hypothermia. Adrenal glands on ultrasonography were judged small in 6. Eight cats could be followed for 14 to 70 months (median: 28). Two were started on DOCP doses ≥2.2 mg/kg (2.2; 2.5) and 6 < 2.2 mg/kg (1.5-2.0 mg/kg, median 1.8) q28 days. Both high-dose cats and 4 low-dose cats needed a dose increase. Desoxycorticosterone pivalate and prednisolone doses at the end of the follow-up period were 1.3 to 3.0 mg/kg (median: 2.3) and 0.08 to 0.5 mg/kg/day (median: 0.3), respectively. Conclusions and Clinical Importance: Desoxycorticosterone pivalate and prednisolone requirements in cats were higher than what is currently used in dogs; thus, a DOCP starting dose of 2.2 mg/kg q28 days and a prednisolone maintenance dose of 0.3 mg/kg/day titrated to the individual need seems warranted. Small adrenal glands (width < 2.7 mm) on ultrasonography in a cat suspected of hypoadrenocorticism can be suggestive of the disease. The apparent predilection of British Shorthaired cats for PH should be further evaluated.
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (2) , 420-427
Open AccessClinical features and long-term management of cats with primary hypoadrenocorticism using desoxycorticosterone pivalate and prednisolone
Background: Primary hypoadrenocorticism (PH) is rare in cats and knowledge about treatment is sparse. Objective: To describe cats with PH with a focus on long-term treatment. Animals: Eleven cats with naturally occurring PH. Methods: Descriptive case series with data on signalment, clinicopathological findings, adrenal width, and doses of desoxycorticosterone pivalate (DOCP) and prednisolone during a follow-up period of >12 months. Results: Cats ranged from 2 to 10 years (median 6.5); 6 cats were British Shorthair. Most common signs were reduced general condition and lethargy, anorexia, dehydration, obstipation, weakness, weight loss, and hypothermia. Adrenal glands on ultrasonography were judged small in 6. Eight cats could be followed for 14 to 70 months (median: 28). Two were started on DOCP doses ≥2.2 mg/kg (2.2; 2.5) and 6 < 2.2 mg/kg (1.5-2.0 mg/kg, median 1.8) q28 days. Both high-dose cats and 4 low-dose cats needed a dose increase. Desoxycorticosterone pivalate and prednisolone doses at the end of the follow-up period were 1.3 to 3.0 mg/kg (median: 2.3) and 0.08 to 0.5 mg/kg/day (median: 0.3), respectively. Conclusions and Clinical Importance: Desoxycorticosterone pivalate and prednisolone requirements in cats were higher than what is currently used in dogs; thus, a DOCP starting dose of 2.2 mg/kg q28 days and a prednisolone maintenance dose of 0.3 mg/kg/day titrated to the individual need seems warranted. Small adrenal glands (width < 2.7 mm) on ultrasonography in a cat suspected of hypoadrenocorticism can be suggestive of the disease. The apparent predilection of British Shorthaired cats for PH should be further evaluated.
- Open Access
- 25 May 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9 (6) , 250
Effects of ACTH-Induced Long-Term Hypercortisolism on the Transcriptome of Canine Visceral Adipose Tissue
Cushing’s syndrome, or hypercortisolism (HC), a common endocrinopathy in adult dogs, is caused by chronic hypercortisolemia. Among different metabolic disorders, this syndrome is associated with enhanced subcutaneous lipolysis and visceral adiposity. However, effects of HC in adipose tissue, especially regarding visceral adipose tissue (VAT), are still poorly understood. Herein, the transcriptomic effects of chronic HC on VAT of dogs were evaluated. For this, subcutaneously implanted ACTH-releasing pumps were used, followed by deep RNA sequencing of the canine VAT. Prolonged HC seems to affect a plethora of regulatory mechanisms in VAT of treated dogs, with 1190 differentially expressed genes (DEGs, p and FDR < 0.01) being found. The 691 downregulated DEGs were mostly associated with functional terms like cell adhesion and migration, intracellular signaling, immune response, extracellular matrix and angiogenesis. Treatment also appeared to modulate local glucocorticoid and insulin signaling and hormonal sensitivity, and several factors, e.g., TIMP4, FGF1, CCR2, CXCR4 and HSD11B1/2, were identified as possible important players in the glucocorticoid-related expansion of VAT. Modulation of their function during chronic HC might present interesting targets for further clinical studies. Similarities in the effects of chronic HC on VAT of dogs and humans are highlighted.
- 25 May 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9 (6) , 250
Open AccessEffects of ACTH-Induced Long-Term Hypercortisolism on the Transcriptome of Canine Visceral Adipose Tissue
Cushing’s syndrome, or hypercortisolism (HC), a common endocrinopathy in adult dogs, is caused by chronic hypercortisolemia. Among different metabolic disorders, this syndrome is associated with enhanced subcutaneous lipolysis and visceral adiposity. However, effects of HC in adipose tissue, especially regarding visceral adipose tissue (VAT), are still poorly understood. Herein, the transcriptomic effects of chronic HC on VAT of dogs were evaluated. For this, subcutaneously implanted ACTH-releasing pumps were used, followed by deep RNA sequencing of the canine VAT. Prolonged HC seems to affect a plethora of regulatory mechanisms in VAT of treated dogs, with 1190 differentially expressed genes (DEGs, p and FDR < 0.01) being found. The 691 downregulated DEGs were mostly associated with functional terms like cell adhesion and migration, intracellular signaling, immune response, extracellular matrix and angiogenesis. Treatment also appeared to modulate local glucocorticoid and insulin signaling and hormonal sensitivity, and several factors, e.g., TIMP4, FGF1, CCR2, CXCR4 and HSD11B1/2, were identified as possible important players in the glucocorticoid-related expansion of VAT. Modulation of their function during chronic HC might present interesting targets for further clinical studies. Similarities in the effects of chronic HC on VAT of dogs and humans are highlighted.
- Open Access
- 30 March 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (4) , 306
Serum Lipidome Signatures of Dogs with Different Endocrinopathies Associated with Hyperlipidemia
Hyperlipidemia (hypertriglyceridemia, hypercholesterolemia) is a common finding in human and veterinary patients with endocrinopathies (e.g., hypothyroidism and hypercortisolism (Cushing’s syndrome; CS)). Despite emerging use of lipidomics technology in medicine, the lipid profiles of these endocrinopathies have not been evaluated and characterized in dogs. The aim of this study was to compare the serum lipidomes of dogs with naturally occurring CS or hypothyroidism with those of healthy dogs. Serum samples from 39 dogs with CS, 45 dogs with hypothyroidism, and 10 healthy beagle dogs were analyzed using a targeted lipidomics approach with liquid chromatography-mass spectrometry. There were significant differences between the lipidomes of dogs with CS, hypothyroidism, and the healthy dogs. The most significant changes were found in the lysophosphatidylcholines, lysophosphatidylethanolamines, lysophosphatidylinositols, phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, ceramides, and sphingosine 1-phosphates. Lipid alterations were especially pronounced in dogs with hypothyroidism. Several changes suggested a more atherogenic lipid profile in dogs with HT than in dogs with CS. In this study, we found so far unknown effects of naturally occurring hypothyroidism and CS on lipid metabolism in dogs. Our findings provide starting points to further examine differences in occurrence of atherosclerotic lesion formation between the two diseases.
- 30 March 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (4) , 306
Open AccessSerum Lipidome Signatures of Dogs with Different Endocrinopathies Associated with Hyperlipidemia
Hyperlipidemia (hypertriglyceridemia, hypercholesterolemia) is a common finding in human and veterinary patients with endocrinopathies (e.g., hypothyroidism and hypercortisolism (Cushing’s syndrome; CS)). Despite emerging use of lipidomics technology in medicine, the lipid profiles of these endocrinopathies have not been evaluated and characterized in dogs. The aim of this study was to compare the serum lipidomes of dogs with naturally occurring CS or hypothyroidism with those of healthy dogs. Serum samples from 39 dogs with CS, 45 dogs with hypothyroidism, and 10 healthy beagle dogs were analyzed using a targeted lipidomics approach with liquid chromatography-mass spectrometry. There were significant differences between the lipidomes of dogs with CS, hypothyroidism, and the healthy dogs. The most significant changes were found in the lysophosphatidylcholines, lysophosphatidylethanolamines, lysophosphatidylinositols, phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, ceramides, and sphingosine 1-phosphates. Lipid alterations were especially pronounced in dogs with hypothyroidism. Several changes suggested a more atherogenic lipid profile in dogs with HT than in dogs with CS. In this study, we found so far unknown effects of naturally occurring hypothyroidism and CS on lipid metabolism in dogs. Our findings provide starting points to further examine differences in occurrence of atherosclerotic lesion formation between the two diseases.
- Open Access
Modified-Live Feline Calicivirus Vaccination Elicits Cellular Immunity against a Current Feline Calicivirus Field Strain in an Experimental Feline Challenge Study
Feline calicivirus (FCV) is a common cat virus associated with oral ulcerations and virulent-systemic disease. Efficacious FCV vaccines protect against severe disease but not against infection. The high genetic diversity of FCV poses a challenge in vaccine design. Protection against FCV has been related to humoral and cellular immunity; the latter has not been studied in detail. This study investigates the cellular and humoral immune response of specified pathogen-free (SPF) cats after modified-live FCV F9 vaccinations and two heterologous FCV challenges by the analysis of lymphocyte subsets, cytokine mRNA transcription levels, interferon (IFN)-γ release assays in peripheral blood mononuclear cells (PBMCs), anti-FCV antibodies, and neutralisation activity. Vaccinated cats developed a Th1 cytokine response after vaccination. Vaccination resulted in antibodies with neutralising activity against the vaccine but not the challenge viruses. Remarkably, IFN-γ-releasing PBMCs were detected in vaccinated cats upon stimulation with the vaccine strain and the first heterologous FCV challenge strain. After the first experimental infection, the mRNA transcription levels of perforin, granzyme B, INF-γ, and antiviral factor MX1 and the number of IFN-γ-releasing PBMCs when stimulated with the first challenge virus were higher in vaccinated cats compared to control cats. The first FCV challenge induced crossneutralising antibodies in all cats against the second challenge virus. Before the second challenge, vaccinated cats had a higher number of IFN-γ-releasing PBMCs when stimulated with the second challenge virus than control cats. After the second FCV challenge, there were less significant differences detected between the groups regarding lymphocyte subsets and cytokine mRNA transcription levels. In conclusion, modified-live FCV vaccination induced cellular but not humoral crossimmunity in SPF cats; innate immune mechanisms, secretory and membranolytic pathways, and IFN-γ-releasing PBMCs seem to be important in the host immune defence against FCV.
Open AccessModified-Live Feline Calicivirus Vaccination Elicits Cellular Immunity against a Current Feline Calicivirus Field Strain in an Experimental Feline Challenge Study
Feline calicivirus (FCV) is a common cat virus associated with oral ulcerations and virulent-systemic disease. Efficacious FCV vaccines protect against severe disease but not against infection. The high genetic diversity of FCV poses a challenge in vaccine design. Protection against FCV has been related to humoral and cellular immunity; the latter has not been studied in detail. This study investigates the cellular and humoral immune response of specified pathogen-free (SPF) cats after modified-live FCV F9 vaccinations and two heterologous FCV challenges by the analysis of lymphocyte subsets, cytokine mRNA transcription levels, interferon (IFN)-γ release assays in peripheral blood mononuclear cells (PBMCs), anti-FCV antibodies, and neutralisation activity. Vaccinated cats developed a Th1 cytokine response after vaccination. Vaccination resulted in antibodies with neutralising activity against the vaccine but not the challenge viruses. Remarkably, IFN-γ-releasing PBMCs were detected in vaccinated cats upon stimulation with the vaccine strain and the first heterologous FCV challenge strain. After the first experimental infection, the mRNA transcription levels of perforin, granzyme B, INF-γ, and antiviral factor MX1 and the number of IFN-γ-releasing PBMCs when stimulated with the first challenge virus were higher in vaccinated cats compared to control cats. The first FCV challenge induced crossneutralising antibodies in all cats against the second challenge virus. Before the second challenge, vaccinated cats had a higher number of IFN-γ-releasing PBMCs when stimulated with the second challenge virus than control cats. After the second FCV challenge, there were less significant differences detected between the groups regarding lymphocyte subsets and cytokine mRNA transcription levels. In conclusion, modified-live FCV vaccination induced cellular but not humoral crossimmunity in SPF cats; innate immune mechanisms, secretory and membranolytic pathways, and IFN-γ-releasing PBMCs seem to be important in the host immune defence against FCV.
- Open Access
Modified-Live Feline Calicivirus Vaccination Reduces Viral RNA Loads, Duration of RNAemia, and the Severity of Clinical Signs after Heterologous Feline Calicivirus Challenge
Feline calicivirus (FCV) is a common cat virus causing clinical signs such as oral ulcerations, fever, reduced general condition, pneumonia, limping and occasionally virulent-systemic disease. Efficacious FCV vaccines protect against severe disease but not against infection. FCV is a highly mutagenic RNA virus whose high genetic diversity poses a challenge in vaccine design. The use of only one modified-live FCV strain over several decades might have driven the viral evolution towards more vaccine-resistant variants. The present study investigated the clinical signs, duration, and amount of FCV shedding, RNAemia, haematological changes and acute phase protein reaction in SPF cats after subcutaneous modified-live single strain FCV vaccination or placebo injection and two subsequent oronasal heterologous FCV challenge infections with two different field strains. Neither clinical signs nor FCV shedding from the oropharynx and FCV RNAemia were detected after vaccination. After the first experimental infection, vaccinated cats had significantly lower clinical scores, less increased body temperature and lower acute phase protein levels than control cats. The viral RNA loads from the oropharynx and duration and amount of RNAemia were significantly lower in the vaccinated animals. No clinical signs were observed in any of the cats after the second experimental infection. In conclusion, FCV vaccination was beneficial for protecting cats from severe clinical signs, reducing viral loads and inflammation after FCV challenge.
Open AccessModified-Live Feline Calicivirus Vaccination Reduces Viral RNA Loads, Duration of RNAemia, and the Severity of Clinical Signs after Heterologous Feline Calicivirus Challenge
Feline calicivirus (FCV) is a common cat virus causing clinical signs such as oral ulcerations, fever, reduced general condition, pneumonia, limping and occasionally virulent-systemic disease. Efficacious FCV vaccines protect against severe disease but not against infection. FCV is a highly mutagenic RNA virus whose high genetic diversity poses a challenge in vaccine design. The use of only one modified-live FCV strain over several decades might have driven the viral evolution towards more vaccine-resistant variants. The present study investigated the clinical signs, duration, and amount of FCV shedding, RNAemia, haematological changes and acute phase protein reaction in SPF cats after subcutaneous modified-live single strain FCV vaccination or placebo injection and two subsequent oronasal heterologous FCV challenge infections with two different field strains. Neither clinical signs nor FCV shedding from the oropharynx and FCV RNAemia were detected after vaccination. After the first experimental infection, vaccinated cats had significantly lower clinical scores, less increased body temperature and lower acute phase protein levels than control cats. The viral RNA loads from the oropharynx and duration and amount of RNAemia were significantly lower in the vaccinated animals. No clinical signs were observed in any of the cats after the second experimental infection. In conclusion, FCV vaccination was beneficial for protecting cats from severe clinical signs, reducing viral loads and inflammation after FCV challenge.
- Open Access
- 1 November 2020
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 34 (6) , 2287-2295
Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release
Background: Glycemic variability (GV) is an indicator of glycemic control and can be evaluated by calculating the SD of blood glucose measurements. In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to conventional therapy reduces GV. In diabetic cats, the influence of GLP-1 analogues on GV is unknown. Objective: To evaluate GV in diabetic cats receiving the GLP-1 analogue exenatide extended release (EER) and insulin. Animals: Thirty client-owned cats with newly diagnosed spontaneous DM. Methods: Retrospective study. Blood glucose curves from a recent prospective placebo-controlled clinical trial generated 1, 3, 6, 10, and 16 weeks after starting therapy were retrospectively evaluated for GV. Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet. Mean blood glucose concentrations were calculated and GV was assessed by SD. Data were analyzed using nonparametric tests. Results: In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93]) and lower compared to placebo at week 6 (3.29 mmol/L [1.95-4.63]; P = .04) and week 10 (4.34 mmol/L [2.43-6.24]; P < .000). Cats achieving remission (1.21 mmol/L [0.23-2.19]) had lower GV compared to those without remission (2.96 mmol/L [1.97-3.96]; P = .01) at week 6. Conclusions and Clinical Importance: The combination of EER, insulin, and a low-carbohydrate diet might be advantageous in the treatment of newly diagnosed diabetic cats.
- 1 November 2020
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 34 (6) , 2287-2295
Open AccessGlycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release
Background: Glycemic variability (GV) is an indicator of glycemic control and can be evaluated by calculating the SD of blood glucose measurements. In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to conventional therapy reduces GV. In diabetic cats, the influence of GLP-1 analogues on GV is unknown. Objective: To evaluate GV in diabetic cats receiving the GLP-1 analogue exenatide extended release (EER) and insulin. Animals: Thirty client-owned cats with newly diagnosed spontaneous DM. Methods: Retrospective study. Blood glucose curves from a recent prospective placebo-controlled clinical trial generated 1, 3, 6, 10, and 16 weeks after starting therapy were retrospectively evaluated for GV. Cats received either EER (200 μg/kg) or 0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet. Mean blood glucose concentrations were calculated and GV was assessed by SD. Data were analyzed using nonparametric tests. Results: In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93]) and lower compared to placebo at week 6 (3.29 mmol/L [1.95-4.63]; P = .04) and week 10 (4.34 mmol/L [2.43-6.24]; P < .000). Cats achieving remission (1.21 mmol/L [0.23-2.19]) had lower GV compared to those without remission (2.96 mmol/L [1.97-3.96]; P = .01) at week 6. Conclusions and Clinical Importance: The combination of EER, insulin, and a low-carbohydrate diet might be advantageous in the treatment of newly diagnosed diabetic cats.
- Open Access
- 3 December 2019
- Published by Springer Nature in Metabolomics
- Vol. 16 (1) , 1-12
Serum lipidome analysis of healthy beagle dogs receiving different diets
Introduction: Food and dietary ingredients have significant effects on metabolism and health.Objective: To evaluate whether and how different diets affected the serum lipidomic profile of dogs.Methods: Sixteen healthy beagles were fed a commercial dry diet for 3 months (control diet). After an overnight fasting period, a blood sample was taken for serum lipidomic profile analysis, and each dog was then randomly assigned to one of two groups. Group 1 was fed a commercial diet (Diet 1) and group 2 was fed a self-made, balanced diet supplemented with linseed oil and salmon oil (Diet 2) for 3 months. After an overnight fasting period, a blood sample was taken from each dog. Serum cholesterol and triacylglycerol analyses were performed and the serum lipidomic profiles were analyzed using targeted liquid chromatography–mass spectrometry.Results: Dogs fed the supplemented self-made diet (Diet 2) had significantly higher omega-3 fatty acid-containing lipids species and significantly lower saturated and mono- and di-unsaturated lipid species. Concentrations of sphingosine 1-phosphate species S1P d16:1 and S1P d17:1 were significantly increased after feeding Diet 2.Conclusion: This study found that different diets had significant effects on the dog’s serum lipidomic profile. Therefore, in studies that include lipidomic analyses, diet should be included as a confounding factor.
- 3 December 2019
- Published by Springer Nature in Metabolomics
- Vol. 16 (1) , 1-12
Open AccessSerum lipidome analysis of healthy beagle dogs receiving different diets
Introduction: Food and dietary ingredients have significant effects on metabolism and health.Objective: To evaluate whether and how different diets affected the serum lipidomic profile of dogs.Methods: Sixteen healthy beagles were fed a commercial dry diet for 3 months (control diet). After an overnight fasting period, a blood sample was taken for serum lipidomic profile analysis, and each dog was then randomly assigned to one of two groups. Group 1 was fed a commercial diet (Diet 1) and group 2 was fed a self-made, balanced diet supplemented with linseed oil and salmon oil (Diet 2) for 3 months. After an overnight fasting period, a blood sample was taken from each dog. Serum cholesterol and triacylglycerol analyses were performed and the serum lipidomic profiles were analyzed using targeted liquid chromatography–mass spectrometry.Results: Dogs fed the supplemented self-made diet (Diet 2) had significantly higher omega-3 fatty acid-containing lipids species and significantly lower saturated and mono- and di-unsaturated lipid species. Concentrations of sphingosine 1-phosphate species S1P d16:1 and S1P d17:1 were significantly increased after feeding Diet 2.Conclusion: This study found that different diets had significant effects on the dog’s serum lipidomic profile. Therefore, in studies that include lipidomic analyses, diet should be included as a confounding factor.